Retroscreen Virology receives €630,000 to start first clinical study of avian influenza vaccine
This article was originally published in Scrip
Executive Summary
The UK CRO Retroscreen Virology is planning to start its first clinical study of a novel, culture-based intranasal vaccine against diverse strains of avian influenza (H5N1), along with other members of a European consortium. Other consortium members include Archimedes Development, the University of Leicester, the National Institute of Biological Standards Control, and Evicom.